In 2022, KDIGO’s diabetes in CKD guidelines recommended long-acting GLP-1 RAs for T2D patients with CKD who need additional glycemic or weight control despite metformin and an SGLT2 inhibitor [68]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.